



PRESS RELEASE

ONE BLOOD, a Stemlife CSR programme

One cord. One hope. A fight against 80+ diseases.

Calling on all Malaysians to help nominate families in need.

Key points

- One Blood helps Malaysian families by providing fully subsidised cord blood banking service for those in their second or third trimester of pregnancy, whose direct family member is suffering or is in remission from a disease that can be treated by cord blood stem cells.
- Haematopoietic stem cells present in cord blood, have been proven useful in the treatment of over 80 diseases including leukaemia, neuroblastoma and thalassaemia.
- Malaysians can nominate their expectant family or friends to receive fully subsidised cord blood banking service.

KUALA LUMPUR, 13 July, 2018 – Stemlife Berhad (“Stemlife” or the “Company”), one of Malaysia’s pioneer and largest cord blood bank has launched its new corporate social responsibility initiative, One Blood, in conjunction with the Cord Blood Awareness month in July and is now calling for nominations from all Malaysians.

Collected at birth, a newborn baby’s cord blood contains haematopoietic stem cells (“HSC”), which have been used successfully to help patients suffering from more than 80 diseases such as leukaemia, neuroblastoma and thalassaemia. By storing cord blood, the family has a ready source of HSC, in case a stem cell transplant is needed in the future. In April this year, Stemlife achieved the prestigious AABB accreditation, an internationally recognised symbol of quality. This is a milestone for Malaysia as more and more countries and hospitals only permit the use of cord blood units processed by an AABB accredited cord blood bank.

One Blood is aimed at contributing back to the community by providing fully subsidised cord blood banking service for those in their second or third trimester of pregnancy, who has a direct family member suffering or in remission from a disease that can be treated by cord blood stem cells.

Malaysians can now nominate someone from their family or circle of friends to receive the fully subsidised cord blood banking service for 21 years worth RM6,600. Families will be selected based on nominations, following a medical background check and an interview. The nominations are open to all Malaysians and all beneficiaries must be delivering their baby in Malaysia.



“We always believe in giving back to the community and this time we are enlisting Malaysians to join us in identifying families who can benefit the most from cord blood banking. We have seen how cord blood has become a gift of life in many real life cases. Through this national movement, we hope to identify families who can benefit from the protection that cord blood banking has to offer,” said Ms Yap Eng Gee, CEO of Stemlife Berhad.

“Cord blood has been used to help over 35,000 patients worldwide and with many clinical trials ongoing, we believe One Blood can make a direct impact to families in need. This is our way of giving back to the society and to thank Malaysians for supporting Stemlife over the last 17 years,” said Mr Michael Weiss, Group CEO and Executive Director of Cordlife Group Limited.

One Blood is open for nomination from now until 15 August 2018. To know more about this program or to submit your nominations, please visit <http://www.stemlife.com/en/one-blood>.

---End---

Editorial contact:

Sharves Bala

PR Director

Citrine One Sdn Bhd

sharves@citrineone.com

Tel: 03 7803 7364 / 016- 669 9290

About Stemlife Bhd

Stemlife is a stem cell bank licensed by the Ministry of Health Malaysia under the Private Healthcare Facilities and Services (PHFS) Act 1998. Established in 2001 and a majority-owned subsidiary of Singapore mainboard listed Cordlife Group Limited, Stemlife offers end-to-end stem cell services of the highest standard and quality through cutting-edge technology and lab processing in accordance with international standards. In April 2018, Stemlife attained international accreditation from AABB, which is the strongest endorsement of Stemlife’s robust medical and technical capabilities. Collectively, more than 60,000 families have entrusted their baby’s cord blood stem cells with Stemlife facility. To-date, Stemlife has successfully released 16 cord blood units for transplantation and assisted in stem cell applications for over 500 cases. For more information, please visit www.stemlife.com.

About Cordlife Group Limited

(Bloomberg: CLGL; Reuters: [CORD.SI](https://www.reuters.com/markets/cordlife))

Incorporated in 2001, Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the



“Group”) is a consumer health company and one of the leading providers of cord blood as well as cord lining banking services in Asia. Cordlife has been listed on the mainboard of Singapore Exchange (SGX: P8A) since March 2012.

Cordlife owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets namely Singapore, Hong Kong, Indonesia, India, Malaysia and the Philippines. In Singapore, Philippines and Indonesia, Cordlife operates the largest private cord blood banks; and is amongst the top three market leaders in India and Malaysia. By January 2018, Cordlife became the market leader in Hong Kong with the acquisition of the largest private cord blood bank in the country, HealthBaby Biotech (Hong Kong) Co., Limited. Through its majority-owned subsidiary, Stemlife Berhad in Malaysia, Cordlife controls an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. Cordlife is also the first Singapore private cord blood bank to provide cord blood and cord lining banking services in Myanmar and Vietnam.

Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services for the mother and child segment including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and other genetic screening services.

The Group's stem cell processing and storage facilities in Singapore, Hong Kong, India and the Philippines are accredited by AABB, the organisation behind the world's gold standard for cord blood banking. In April 2018, Stemlife Berhad, being the pioneer and the largest cord blood bank in Malaysia, has also achieved AABB accreditation. Cordlife Singapore is accredited by FACT-Netcord, another world-class accreditation body for cord blood banks globally. This makes Cordlife Singapore one of just six cord blood banks in the world to be accredited by both AABB and FACT-Netcord simultaneously. The Group's majority-owned Hong Kong Screening Centre, HealthBaby and Cordlife India also attained accreditation from the College of American Pathologists (“CAP”) for meeting the highest industry standards for laboratory services. These quality achievements underpin the Group’s commitment to providing the highest service quality for clients. For more information, please visit <http://cordlife.listedcompany.com>.